ANI Pharmaceuticals (ANIP) Form 144: 47,012 Shares Proposed Sale

ANI Pharmaceuticals Form 144 notice reports a proposed sale of 47,012 shares of common stock through Merrill Lynch on NASDAQ with an aggregate market value of $4,243,702.53 and an approximate sale date of 08/20/2025.

Rhea-AI Filing Summary

ANI Pharmaceuticals Form 144 notice reports a proposed sale of 47,012 shares of common stock through Merrill Lynch on NASDAQ with an aggregate market value of $4,243,702.53 and an approximate sale date of 08/20/2025. The securities were acquired on 11/19/2021 as a company buyout from ANI Pharmaceuticals and the indicated payment is a compensatory payment. The filing also lists recent sales by the same seller on 08/14/2025 (47,010 shares) and 08/15/2025 (52,990 shares). The notice contains the seller's certification that they are unaware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR Form 144 discloses scheduled insider-related share sales totaling 47,012 shares via Merrill Lynch on NASDAQ.

The filing provides clear transactional detail: class (common), exact share count (47,012), market value ($4,243,702.53), acquisition date (11/19/2021) and nature of acquisition (company buyout). It also records two recent sales by the same seller in mid-August 2025, which may indicate ongoing disposition activity. The notice includes the seller's attestation regarding material nonpublic information, consistent with Rule 144 requirements. From a compliance standpoint, the form appears complete for the proposed sale.

Corporate Governance Expert

TL;DR The filer documented required disclosures for a Rule 144 sale and recent related transactions, meeting formal signature attestation.

The form names the broker (Merrill Lynch), identifies the trading venue (NASDAQ), and specifies acquisition and payment details (compensatory payment). Inclusion of the seller's prior August sales provides useful context for monitoring insider disposition patterns. The signed attestation regarding absence of undisclosed adverse information is standard and required; no governance violations are alleged in the filing itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2025 - 04:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001870913
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ANI PHARMACEUTICALS INC
SEC File Number	001-31812
Address of Issuer	210 MAIN STREET WEST BAUDETTE MINNESOTA 56623
Phone	2186343500
Name of Person for Whose Account the Securities are To Be Sold	Shanmugam Muthusamy
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill Lynch 3455 Peachtree Road Atlanta GA 30326	47012	4243702.53	21688772	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/19/2021	Company Buyout	ANI Pharmaceuticals			47012	08/20/2025	compensatory payment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Muthusamy Shanmugam 210 Main Street West Baudette MN 56623	common	08/14/2025	47010	4206603.82
Muthusamy Shanmugam 210 Main Street West Baudette MN 56623	Common	08/15/2025	52990	4618063.56

144: Remarks and Signature

Remarks
Date of Notice	08/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Muthusamy Shanmugam
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)